WallStSmart

Palantir Technologies Inc. (PLTR)vsSanofi ADR (SNY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Sanofi ADR generates 806% more annual revenue ($47.35B vs $5.22B). PLTR leads profitability with a 43.7% profit margin vs 16.0%. PLTR appears more attractively valued with a PEG of 2.90. PLTR earns a higher WallStSmart Score of 73/100 (B).

PLTR

Strong Buy

73

out of 100

Grade: B

Growth: 10.0Profit: 9.5Value: 2.0Quality: 9.0
Piotroski: 5/9Altman Z: 4.62

SNY

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 6.5Value: 5.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

PLTRSignificantly Overvalued (-64.3%)

Margin of Safety

-64.3%

Fair Value

$78.43

Current Price

$137.80

$59.37 premium

UndervaluedFair: $78.43Overvalued
SNYUndervalued (+25.0%)

Margin of Safety

+25.0%

Fair Value

$62.70

Current Price

$43.31

$19.39 discount

UndervaluedFair: $62.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

PLTR6 strengths · Avg: 10.0/10
Market CapQuality
$328.55B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
32.6%10/10

Every $100 of equity generates 33 in profit

Profit MarginProfitability
43.7%10/10

Keeps 44 of every $100 in revenue as profit

Operating MarginProfitability
46.2%10/10

Strong operational efficiency at 46.2%

Revenue GrowthGrowth
84.7%10/10

Revenue surging 84.7% year-over-year

EPS GrowthGrowth
325.0%10/10

Earnings expanding 325.0% YoY

SNY4 strengths · Avg: 8.8/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Market CapQuality
$103.45B9/10

Large-cap with strong market position

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$1.68B8/10

Generating 1.7B in free cash flow

Areas to Watch

PLTR3 concerns · Avg: 2.0/10
PEG RatioValuation
2.902/10

Expensive relative to growth rate

P/E RatioValuation
154.0x2/10

Premium valuation, high expectations priced in

Price/BookValuation
44.6x2/10

Trading at 44.6x book value

SNY3 concerns · Avg: 2.3/10
Return on EquityProfitability
6.6%3/10

ROE of 6.6% — below average capital efficiency

PEG RatioValuation
3.762/10

Expensive relative to growth rate

EPS GrowthGrowth
-11.7%2/10

Earnings declined 11.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : PLTR

The strongest argument for PLTR centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 43.7% and operating margin at 46.2%. Revenue growth of 84.7% demonstrates continued momentum.

Bull Case : SNY

The strongest argument for SNY centers on Price/Book, Market Cap, Operating Margin. Profitability is solid with margins at 16.0% and operating margin at 20.0%.

Bear Case : PLTR

The primary concerns for PLTR are PEG Ratio, P/E Ratio, Price/Book. A P/E of 154.0x leaves little room for execution misses.

Bear Case : SNY

The primary concerns for SNY are Return on Equity, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

PLTR profiles as a growth stock while SNY is a mature play — different risk/reward profiles.

PLTR carries more volatility with a beta of 1.52 — expect wider price swings.

PLTR is growing revenue faster at 84.7% — sustainability is the question.

SNY generates stronger free cash flow (1.7B), providing more financial flexibility.

Bottom Line

PLTR scores higher overall (73/100 vs 51/100), backed by strong 43.7% margins and 84.7% revenue growth. SNY offers better value entry with a 25.0% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Palantir Technologies Inc.

TECHNOLOGY · SOFTWARE - INFRASTRUCTURE · USA

Palantir Technologies Inc. creates and implements software platforms for the intelligence community in the United States to assist in counterterrorism investigations and operations. The company is headquartered in Denver, Colorado.

Visit Website →

Sanofi ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.

Want to dig deeper into these stocks?